Share this post:
Adult stem cells may be a novel therapeutic option for treating Scleroderma, or Systemic Sclerosis (SSc), a group of rare diseases that involve the hardening and tightening of the skin and connective tissues, which provide the framework and support for the body.
Scleroderma is a progressive auto-immune condition that has very few treatment options. It can either be localized to the skin (Morphea) or systemic with the potential of severe organ involvement, affecting blood vessels, internal
Scleroderma affects women more often than men and occurs mostly between the ages of 30 and 50. Scleroderma results from an
overproduction and accumulation of collagen in body tissues. Although it’s not clear what prompts such abnormal collagen production, the body’s immune system appears to play a role.
During the study, approximately 60 mL of fat tissue was removed from the abdomen or flanks of each participating patient using a local tumescent liposuction procedure. The fat was separated via centrifuge to isolate the SVF, and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient. All patients were monitored for adverse events.
The collected results demonstrate exceptional patient safety with low complication rates and underscore the safety of autologous stem cell therapy in general. Few adverse events were reported, and those were overwhelmingly of mild and transient nature, such as the expected soreness at the site of liposuction and occasional headache.
“We conducted our study at multiple treatment centers in the United States, and the results demonstrate overwhelmingly that this new type of patient-specific medical treatment is safe,” the scientists who authored the study wrote in their final report. “It is hoped that our report may be a beneficial starting point for physicians considering this new approach to disease, and helpful also to regulatory agencies seeking to advance policy for the benefit of patients.”
The safety study was published in the Journal of Clinical Medicine Research and co-authored by U.S. Stem Cell, Inc. Chief Science Officer Kristin Comella, PhD, as well as Michelle Parlo, PA, Rosemary Daly, DO, Vincent Depasquale, DC, Eric Edgerton, DC, Patrick Mallory, DO, Roy Schmidt, MD, Walter P. Drake, PhD.
Stem cells from fat tissue offer a novel therapy for patients with damaged tissue due to their ability to self-renew and promote a healing cascade. SVF injected into patients may reduce inflammation, promote healing, and repair damaged/scarred tissue. SVF can be isolated from fat (adipose) tissue in a simple outpatient stem cell procedure that takes about 30-90 minutes and can be done under local anesthesia, using a mini-lipoaspirate technique. The stem cells can then be infused or injected after the mini-liposuction.
Cells from fat tissue are quickly becoming the preferred source for in-clinic therapies due to the safe harvesting process, high number of stem cells and low number of leukocytes, as compared to bone marrow. In fact, approximately 500 times more stem cells can be obtained from fat than bone marrow. There is also a high amount of pericytes in fat tissue as a result of the extensive vascular network. The use of SVF has been reported in a variety of indications, including osteoarthritis, degenerative disc disease, sclerosis, tendinopathy, congestive heart failure, chronic obstructive pulmonary disease (COPD), radiation necrosis, xerostomia, and multiple sclerosis.
Our team has successfully treated over 7,000 patients using stem cells from fat with very few safety concerns reported. We are extremely encouraged by the positive patient results we are seeing from our physician-based treatments. Stem cells possess enormous regenerative potential. One day, stem cell therapy will be the gold standard of care for the treatment of most degenerative diseases.
To find out how stem cell therapy can help you improve your life, please request your free, no-obligation consultation on our website: http://usstemcellclinic.com/contact-us or by calling 954-510-3150.